Kristin J Redmond1, Daniel Sciubba2, Majid Khan3, Chengcheng Gui4, Sheng-Fu Larry Lo2, Ziya L Gokaslan5, Brianne Leaf4, Lawrence Kleinberg4, Jimm Grimm4, Xiaobu Ye2, Michael Lim2. 1. Department of Radiation Oncology and Molecular Radiation Sciences, The John Hopkins University, Baltimore, Maryland. Electronic address: kjanson3@jhmi.edu. 2. Neurological Surgery, The John Hopkins University, Baltimore, Maryland. 3. Radiology, The John Hopkins University, Baltimore, Maryland. 4. Department of Radiation Oncology and Molecular Radiation Sciences, The John Hopkins University, Baltimore, Maryland. 5. Department of Neurological Surgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island.
Abstract
PURPOSE: In patients with spinal instability, cord compression, or neurologic deficits, the standard of care is surgery followed by radiation therapy (RT). Recurrence rates after conventional RT remain high. The purpose of this study is to prospectively examine the efficacy of postoperative stereotactic body RT (SBRT) in patients who have undergone surgical intervention for spine metastases. We hypothesize that postoperative SBRT to the spine would be associated with higher local control than historical rates after conventional RT. METHODS AND MATERIALS: Thirty-five adult patients with a Karnofsky Performance Status score ≥40 and spine metastases from solid tumors with no prior overlapping RT and target volumes ≤3 consecutive vertebral levels were enrolled. Thirty-three patients were treated. Two patients underwent treatment to 2 target volumes for a total of 35 target volumes. All patients received SBRT 30 Gy in 5 fractions. Patients were followed with neurological examinations and computed tomography and/or magnetic resonance imaging every 3 months. Neurologic function was assessed at the same time points using the American Spinal Injury Association (ASIA) impairment score. Pain was rated according to the 10-point visual analogue scale and MD Anderson Cancer Center brief pain index. Toxicity was recorded according to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4. The primary objective was the rate of radiographic local recurrence at 12 months after completion of SBRT. RESULTS: Patient characteristics were as follows: 34.3% had radioresistant primaries; 71.4% were ASIA E and the remainder ASIA D; and the median baseline Karnofsky Performance Status score was 70 (range, 50-100). Radiographic and symptomatic local control at 1 year were 90% (95% confidence interval, 76%-98%). The median time to recurrence in these 3 patients was 3.5 months (range, 3.4-5.8 months), all had radiosensitive tumors, and all recurrences were epidural. No patients experienced wound dehiscence, hardware failure, or spinal cord myelopathy. The median time to return to systemic therapy was 0.5 months (range, 0-9.4 months). CONCLUSIONS: This prospective study of postoperative spine SBRT demonstrates excellent local control with low toxicity. These data suggest superior rates of local control compared with conventional RT; however, a formal comparative study is warranted.
PURPOSE: In patients with spinal instability, cord compression, or neurologic deficits, the standard of care is surgery followed by radiation therapy (RT). Recurrence rates after conventional RT remain high. The purpose of this study is to prospectively examine the efficacy of postoperative stereotactic body RT (SBRT) in patients who have undergone surgical intervention for spine metastases. We hypothesize that postoperative SBRT to the spine would be associated with higher local control than historical rates after conventional RT. METHODS AND MATERIALS: Thirty-five adult patients with a Karnofsky Performance Status score ≥40 and spine metastases from solid tumors with no prior overlapping RT and target volumes ≤3 consecutive vertebral levels were enrolled. Thirty-three patients were treated. Two patients underwent treatment to 2 target volumes for a total of 35 target volumes. All patients received SBRT 30 Gy in 5 fractions. Patients were followed with neurological examinations and computed tomography and/or magnetic resonance imaging every 3 months. Neurologic function was assessed at the same time points using the American Spinal Injury Association (ASIA) impairment score. Pain was rated according to the 10-point visual analogue scale and MD Anderson Cancer Center brief pain index. Toxicity was recorded according to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4. The primary objective was the rate of radiographic local recurrence at 12 months after completion of SBRT. RESULTS:Patient characteristics were as follows: 34.3% had radioresistant primaries; 71.4% were ASIA E and the remainder ASIA D; and the median baseline Karnofsky Performance Status score was 70 (range, 50-100). Radiographic and symptomatic local control at 1 year were 90% (95% confidence interval, 76%-98%). The median time to recurrence in these 3 patients was 3.5 months (range, 3.4-5.8 months), all had radiosensitive tumors, and all recurrences were epidural. No patients experienced wound dehiscence, hardware failure, or spinal cord myelopathy. The median time to return to systemic therapy was 0.5 months (range, 0-9.4 months). CONCLUSIONS: This prospective study of postoperative spine SBRT demonstrates excellent local control with low toxicity. These data suggest superior rates of local control compared with conventional RT; however, a formal comparative study is warranted.
Authors: Roman O Kowalchuk; Michael R Waters; K Martin Richardson; Kelly Spencer; James M Larner; Jason P Sheehan; William H McAllister; Charles R Kersh Journal: J Radiosurg SBRT Date: 2020
Authors: Oluwaseun O Akinduro; Gaetano De Biase; Anshit Goyal; Jenna H Meyer; Sukhwinder J S Sandhu; Roman O Kowalchuk; Daniel M Trifiletti; Jason Sheehan; Kenneth W Merrell; Sujay A Vora; Daniel F Broderick; Michelle J Clarke; Mohamad Bydon; Jamal McClendon; Maziyar A Kalani; Alfredo Quiñones-Hinojosa; Kingsley Abode-Iyamah Journal: J Neurooncol Date: 2022-01-07 Impact factor: 4.130
Authors: Giuseppe Di Perna; Fabio Cofano; Cristina Mantovani; Serena Badellino; Nicola Marengo; Marco Ajello; Ludovico Maria Comite; Giuseppe Palmieri; Fulvio Tartara; Francesco Zenga; Umberto Ricardi; Diego Garbossa Journal: J Bone Oncol Date: 2020-09-26 Impact factor: 4.072
Authors: Julio C Furlan; Jefferson R Wilson; Eric M Massicotte; Arjun Sahgal; Michael G Fehlings Journal: Neuro Oncol Date: 2022-01-05 Impact factor: 13.029
Authors: Roman O Kowalchuk; David Cousins; Kelly M Spencer; K Martin Richardson; James M Larner; Timothy N Showalter; William H McAllister; Jason P Sheehan; C Ronald Kersh; Sunil W Dutta Journal: Rep Pract Oncol Radiother Date: 2021-12-30
Authors: Sangkyu Lee; Dale Michael Lovelock; Alex Kowalski; Kate Chapman; Robert Foley; Mary Gil; Gerri Pastrana; Daniel S Higginson; Yoshiya Yamada; Lei Zhang; James Mechalakos; Ellen Yorke Journal: J Appl Clin Med Phys Date: 2021-10-28 Impact factor: 2.102